Popp-Snijders C, Lomecky-Janousek M Z, Schouten J A, van der Veen E A
Diabetologia. 1984 Nov;27(5):514-6. doi: 10.1007/BF00290386.
Erythrocytes from diabetic patients before and after treatment with the aldose reductase inhibitor, sorbinil, were analyzed by a capillary gas chromatographic method for sorbitol and myo-inositol. The mean erythrocyte sorbitol level in the diabetic patients was significantly higher than in the control subjects (13.1 +/- 0.9 and 5.2 +/- 0.3 nmol/ml erythrocytes, respectively, mean +/- SEM, p less than 0.001). The mean erythrocyte myo-inositol level in diabetic patients was not different from that in control subjects (43.2 +/- 2.9 and 40.5 +/- 1.9 nmol/ml erythrocytes, respectively). Sorbinil treatment reduced the elevated sorbitol levels in the diabetic patients to normal or slightly below normal, but did not affect the erythrocyte myo-inositol concentration. It is concluded that the erythrocyte is not a suitable model to monitor a possible effect of sorbinil on myo-inositol concentration in less accessible tissues.
采用毛细管气相色谱法对糖尿病患者在使用醛糖还原酶抑制剂索比尼尔治疗前后的红细胞进行山梨醇和肌醇分析。糖尿病患者红细胞山梨醇的平均水平显著高于对照组（分别为13.1±0.9和5.2±0.3 nmol/ml红细胞，均值±标准误，p<0.001）。糖尿病患者红细胞肌醇的平均水平与对照组无差异（分别为43.2±2.9和40.5±1.9 nmol/ml红细胞）。索比尼尔治疗使糖尿病患者升高的山梨醇水平降至正常或略低于正常，但不影响红细胞肌醇浓度。结论是，红细胞并非监测索比尼尔对较难检测组织中肌醇浓度可能产生影响的合适模型。
